Developing New T Cell Immunotherapies for Difficult Solid Tumors: Prof. George Coukos, Department of Oncology UNIL-CHUV

X-Health.show - meet the future of healthcare

Have a glimpse into the future of cancer treatment where an army of your own tiny soldiers fiercely combats the most stubborn cancers, even at late stage. They’re called T cells. My today’s guest has worked on immunotherapies that arm T cells, patient’s own white blood cells with weapons agains tumors to infuse them back to the patient’s body.

Whether you’re an oncologist or a nonspecialist, you may be sure you’ll learn a tonne from this episode.

You’ll hear about

• how tumors suppress anti-cancer immune response
• why solid tumors in ovarian cancer, colon cancer, gastro-intestinal cancer, pancreatic cancer, and some breast cancers are more challenging for immunotherapies
• melanoma, lung cancer
• TIL therapies
• adoptive T cell therapies
• autologous dendritic cell vaccine
• and patient experience

Professor George Coukos is on a mission to find a cure for the most difficult cancers. Trained as an MD and obstetrician-gynaecologist, he studied and researched cell biology and oncology at the University of Pennsylvania, which led to the discovery of spontaneous anti-tumor response in ovarian cancer. Now he leads major oncology research institutions in Lausanne, Switzerland, to develop novel T cell therapy approaches for solid tumors. He’s the director of Department of Oncology at the University of Lausanne (UNIL) and Lausanne University Hospital (CHUV), as well as the local branch of Ludwig Institute for Cancer Research. An esteemed researcher with over 200 publications, known for the development of combinational immune therapies that have been approved for lung, liver, and kidney cancers.

To follow Prof. Coukos and his colleagues' recent developments go to
https://www.unil.ch/dof/home.html

https://www.ludwigcancerresearch.org/location/lausanne/

If you've enjoyed listening, you'll make us happy by clicking "Follow" on X-Health.show and leaving a review.
The information in this podcast is for informational purposes only and should not be considered medical advice. If you have any medical questions, please consult your healthcare practitioner. The opinions on the show are Alex's or her guests. The podcast does not make any responsibility or warranties about guests statements or credibility. While the podcast makes every effort to ensure that the information shared is accurate, please let us know if you have any comments, suggestions or corrections.

บท

1. Prof. George Coukos, Department of Oncology UNIL-CHUV (00:00:00)

2. Metastatic Melanoma Complete Response to TIL Treatment (00:01:23)

3. Autologous Personalized Treatment for Solid Tumors (00:05:19)

4. Early Research into Immunotherapies: Steven Rosenberg (00:08:23)

5. Spontaneous Anti-Tumor Response in Ovarian Cancer (00:10:09)

6. Immunotherapies: Drug Combinations, T Cell Therapies, CAR T Cell Therapy in Blood Cancers (00:14:14)

7. Challenges of CAR T Cell Therapy in Solid Tumors (00:18:35)

8. Developing Effective Immunotherapies for Solid Tumors, Starting from More Immunogenic Tumors: Melanoma, Lung Cancer (00:20:28)

9. Clinical Trial and Patient-Reported Outcomes (00:26:44)

10. Why Ovarian, Colon, Gastro-Intestinal, Some Breast Cancers Are More Challenging for T Cell Therapies? (00:30:55)

11. Second Generation of T Cell Therapy: NeoTIL (00:38:14)

12. Personalized Dendritic Cell Vaccine (00:42:18)

13. When Will These Therapies Be Available for Patients (00:45:30)

14. We Owe It to the Patients (00:51:45)

15. Enabling Accelerating Conditions for Cancer Research in Europe (00:55:42)

16. Convergence of Different Innovation Areas to Support the Breakthroughs, AI Role (01:08:34)

17. Follow X-Health.show, Disclaimer (01:14:24)